---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-107419"
form_type: "8-K"
ticker: "EWTX"
cik: "0001710072"
company_name: "Edgewise Therapeutics, Inc."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:49:46.109387+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Edgewise Q3 net loss $40.7M ($0.39/sh); cash $563.3M; GRAND CANYON data Q4 2026

## Summary
- Cash, equivalents and marketable securities $563.3M at Sep 30, 2025.
- R&D expense $37.5M (up $3.9M QoQ) driven by EDG-15400 Phase 1 start and CIRRUS-HCM activity.
- Net loss $40.7M ($0.39 per share) vs $36.1M ($0.34) prior quarter.
- GRAND CANYON pivotal Becker cohort (175 enrolled) on track for topline readout in Q4 2026.
- EDG-7500 CIRRUS-HCM program update expected Q4 2025; EDG-15400 Phase 1 data H1 2026.

## SEC filing metadata
- accession: 0001104659-25-107419
- form_type: 8-K
- ticker: EWTX
- cik: 0001710072
- company_name: Edgewise Therapeutics, Inc.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710072/000110465925107419/0001104659-25-107419-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710072/000110465925107419/tm2529979d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-107419
- JSON: https://secwatch.observer/filing/0001104659-25-107419.json
- Plain text: https://secwatch.observer/filing/0001104659-25-107419.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.